Evidence map›Paper›PMID 28385805›Full record

GuidelineAnnals of the rheumatic diseases2017

2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative.

Rohit Aggarwal, Lisa G Rider, Nicolino Ruperto, Nastaran Bayat, Brian Erman, Brian M Feldman, Chester V Oddis, Anthony A Amato, Hector Chinoy, Robert G Cooper and 19 more

2 registry-linked trialsAbstract readConsensus StatementPractice GuidelineValidation Study
In one paragraph

Guideline in Annals of the rheumatic diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 84 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05832034 phase2 / phase3active not recruitingnot on this mapstarted 2021, after this paper: background citation

Treatment With add-on IVIg in Myositis Early In the diSease Course May be sUperior to Steroids Alone for Reaching CLinical improvemEnt

TypeinterventionalSponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Ran2021 to 2026Enrolled44ConditionsInflammatory Myopathy, Idiopathic, Dermatomyositis, Antisynthetase Syndrome, Immune-Mediated Necrotizing MyopathyArmsImmune Globulin Intravenous (Human), Placebo
NCT07564271 withdrawnnot on this mapstarted 2025, after this paper: background citation

Real-world Experience With Deucravacitinib for the Treatment of Idiopathic Inflammatory Myopathies -- a Prospective Observational Study

TypeobservationalSponsorPeking University People's HospitalRan2025 to 2026Enrolled0ConditionsIdiopathic Inflammatory Myopathies (IIMs)ArmsDeucravacitinib 6mg po qd
3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Observational

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

29 authors.

Rohit AggarwalUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Lisa G RiderNIEHS, NIH, Bethesda, Maryland, USA.
Nicolino RupertoIstituto Giannina Gaslini, Pediatria II - Rheumatologia, PRINTO, Genoa, Italy.
Nastaran BayatNIEHS, NIH, Bethesda, Maryland, USA.
Brian ErmanSocial and Scientific Systems, Inc., Durham, North Carolina, USA.
Brian M FeldmanThe Hospital for Sick Children, Toronto, Ontario, Canada.
Chester V OddisUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Anthony A AmatoBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Hector ChinoyCentral Manchester University Hospitals NHS Foundation Trust, University of Manchester, Manchester, UK.
Robert G CooperUniversity of Liverpool, Liverpool, UK.
Maryam DastmalchiKarolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
David FiorentinoStanford University, Redwood City, California, USA.
David IsenbergUniversity College London, London, UK.
James D KatzNIEHS, NIH, Bethesda, Maryland, USA.
Andrew MammenJohns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Marianne de VisserAcademic Medical Center, Amsterdam, The Netherlands.
Steven R YtterbergMayo Clinic, Rochester, Minnesota, USA.
Ingrid E LundbergKarolinska University Hospital, Karolinska Institute, Stockholm, Sweden.
Lorinda ChungStanford University, Redwood City, California, USA.
Katalin DankoUniversity of Debrecen, Debrecen, Hungary.
Ignacio García-De la TorreHospital General de Occidente de la Secretaría de Salud and University of Guadalajara, Guadalajara, México.
Yeong Wook SongGraduate School of Convergence Science and Technology and Seoul National University Hospital, Seoul, Korea.
Luca VillaIstituto Giannina Gaslini, Pediatria II - Rheumatologia, PRINTO, Genoa, Italy.
Mariangela RinaldiIstituto Giannina Gaslini, Pediatria II - Rheumatologia, PRINTO, Genoa, Italy.
Howard RocketteUniversity of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Peter A LachenbruchNIEHS, NIH, Bethesda, Maryland, USA.
Frederick W MillerNIEHS, NIH, Bethesda, Maryland, USA.
Jiri VencovskyCharles University, Prague, Czech Republic.
International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation

Funding

Clinical Support Services for the NIAMS Intramural Research ProgramZIDAR041180 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI COLBERT, ROBERT · 2009 to 2025
$119.2M
Clinical Training in RheumatologyZIEAR041176 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI COLBERT, ROBERT · 2009 to 2025
$29.8M
Muscle Disease UnitZIAAR041203 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI MAMMEN, ANDREW · 2015 to 2025
$19.7M
Assessment, Therapy and Prevention Of Autoimmune DiseaseZIAES101081 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI RIDER, LISA · 2009 to 2025
$17.6M
Studies of the Natural History of Rheumatic DiseasesZIAAR041170 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI HASNI, SARFARAZ · 2009 to 2025
$11.1M
Intramural NIH HHS Z99 ES999999Intramural NIH HHS ZIA ES101081Medical Research Council MR/K006312/1Medical Research Council MR/N003322/1Medical Research Council MR/P020941/1
6 · The paper itself

Abstract

To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. Consensus was reached for a conjoint analysis-based continuous model using absolute per cent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (p<0.001). The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute per cent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.

Indexed as

Severity of Illness IndexAdolescentAdultChildChild, PreschoolConsensusDermatomyositisHumansOutcome Assessment, Health CarePolymyositisRandomized Controlled Trials as TopicSensitivity and SpecificityDermatomyositisPolymyositisTreatment

Identifiers

PMID28385805
PMCPMC5496443

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.